213 related articles for article (PubMed ID: 35204703)
1. SLC26A9 as a Potential Modifier and Therapeutic Target in Cystic Fibrosis Lung Disease.
Gorrieri G; Zara F; Scudieri P
Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204703
[TBL] [Abstract][Full Text] [Related]
2. The anion transporter SLC26A9 localizes to tight junctions and is degraded by the proteasome when co-expressed with F508del-CFTR.
Sato Y; Thomas DY; Hanrahan JW
J Biol Chem; 2019 Nov; 294(48):18269-18284. PubMed ID: 31645438
[TBL] [Abstract][Full Text] [Related]
3. Separating the contributions of SLC26A9 and CFTR to anion secretion in primary human bronchial epithelia.
Larsen MB; Choi JJ; Wang X; Myerburg MM; Frizzell RA; Bertrand CA
Am J Physiol Lung Cell Mol Physiol; 2021 Dec; 321(6):L1147-L1160. PubMed ID: 34668421
[TBL] [Abstract][Full Text] [Related]
4. Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9.
Pinto MC; Quaresma MC; Silva IAL; Railean V; Ramalho SS; Amaral MD
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884866
[TBL] [Abstract][Full Text] [Related]
5. Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.
Strug LJ; Gonska T; He G; Keenan K; Ip W; Boëlle PY; Lin F; Panjwani N; Gong J; Li W; Soave D; Xiao B; Tullis E; Rabin H; Parkins MD; Price A; Zuberbuhler PC; Corvol H; Ratjen F; Sun L; Bear CE; Rommens JM
Hum Mol Genet; 2016 Oct; 25(20):4590-4600. PubMed ID: 28171547
[TBL] [Abstract][Full Text] [Related]
6. Alternative chloride transport pathways as pharmacological targets for the treatment of cystic fibrosis.
Quesada R; Dutzler R
J Cyst Fibros; 2020 Mar; 19 Suppl 1():S37-S41. PubMed ID: 31662238
[TBL] [Abstract][Full Text] [Related]
7. Loss of Slc26a9 anion transporter alters intestinal electrolyte and HCO3(-) transport and reduces survival in CFTR-deficient mice.
Liu X; Li T; Riederer B; Lenzen H; Ludolph L; Yeruva S; Tuo B; Soleimani M; Seidler U
Pflugers Arch; 2015 Jun; 467(6):1261-75. PubMed ID: 24965066
[TBL] [Abstract][Full Text] [Related]
8. Slc26a9 is inhibited by the R-region of the cystic fibrosis transmembrane conductance regulator via the STAS domain.
Chang MH; Plata C; Sindic A; Ranatunga WK; Chen AP; Zandi-Nejad K; Chan KW; Thompson J; Mount DB; Romero MF
J Biol Chem; 2009 Oct; 284(41):28306-28318. PubMed ID: 19643730
[TBL] [Abstract][Full Text] [Related]
9. Functional interaction of the cystic fibrosis transmembrane conductance regulator with members of the SLC26 family of anion transporters (SLC26A8 and SLC26A9): physiological and pathophysiological relevance.
El Khouri E; Touré A
Int J Biochem Cell Biol; 2014 Jul; 52():58-67. PubMed ID: 24530837
[TBL] [Abstract][Full Text] [Related]
10. The SLC26A9 inhibitor S9-A13 provides no evidence for a role of SLC26A9 in airway chloride secretion but suggests a contribution to regulation of ASL pH and gastric proton secretion.
Jo S; Centeio R; Park J; Ousingsawat J; Jeon DK; Talbi K; Schreiber R; Ryu K; Kahlenberg K; Somoza V; Delpiano L; Gray MA; Amaral MD; Railean V; Beekman JM; Rodenburg LW; Namkung W; Kunzelmann K
FASEB J; 2022 Nov; 36(11):e22534. PubMed ID: 36183361
[TBL] [Abstract][Full Text] [Related]
11. SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR.
Eastman AC; Pace RG; Dang H; Aksit MA; Vecchio-Pagán B; Lam AN; O'Neal WK; Blackman SM; Knowles MR; Cutting GR
J Cyst Fibros; 2021 Sep; 20(5):851-856. PubMed ID: 33674211
[TBL] [Abstract][Full Text] [Related]
12. Identification of single nucleotide variants in SLC26A9 gene in patients with cystic fibrosis (p.Phe508del homozygous) and its association to Orkambi® (Lumacaftor and Ivacaftor) response in vitro.
Santos LG; Pereira SV; Kmit AHP; Bonadia LC; Bertuzzo CS; Ribeiro JD; Mazzola TN; Marson FAL
Gene; 2023 Jun; 871():147428. PubMed ID: 37068695
[TBL] [Abstract][Full Text] [Related]
13. Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients.
Kmit A; Marson FAL; Pereira SV; Vinagre AM; Leite GS; Servidoni MF; Ribeiro JD; Ribeiro AF; Bertuzzo CS; Amaral MD
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1323-1331. PubMed ID: 30716472
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis.
Lam AN; Aksit MA; Vecchio-Pagan B; Shelton CA; Osorio DL; Anzmann AF; Goff LA; Whitcomb DC; Blackman SM; Cutting GR
J Clin Invest; 2020 Jan; 130(1):272-286. PubMed ID: 31581148
[TBL] [Abstract][Full Text] [Related]
15. Hydrokinetic pancreatic function and insulin secretion are moduled by Cl
Li T; di Stefano G; Raza GS; Sommerer I; Riederer B; Römermann D; Tan X; Tan Q; Pallagi P; Hollenbach M; Herzig KH; Seidler U
Acta Physiol (Oxf); 2022 Jan; 234(1):e13729. PubMed ID: 34525257
[TBL] [Abstract][Full Text] [Related]
16. Expression of SLC26A9 in Airways and Its Potential Role in Asthma.
Ousingsawat J; Centeio R; Schreiber R; Kunzelmann K
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328418
[TBL] [Abstract][Full Text] [Related]
17. Targeting ion channels in cystic fibrosis.
Mall MA; Galietta LJ
J Cyst Fibros; 2015 Sep; 14(5):561-70. PubMed ID: 26115565
[TBL] [Abstract][Full Text] [Related]
18. Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities.
Li W; Soave D; Miller MR; Keenan K; Lin F; Gong J; Chiang T; Stephenson AL; Durie P; Rommens J; Sun L; Strug LJ
Hum Genet; 2014 Feb; 133(2):151-61. PubMed ID: 24057835
[TBL] [Abstract][Full Text] [Related]
19. The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9.
Bertrand CA; Mitra S; Mishra SK; Wang X; Zhao Y; Pilewski JM; Madden DR; Frizzell RA
Am J Physiol Lung Cell Mol Physiol; 2017 Jun; 312(6):L912-L925. PubMed ID: 28360110
[TBL] [Abstract][Full Text] [Related]
20. SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia.
Bertrand CA; Zhang R; Pilewski JM; Frizzell RA
J Gen Physiol; 2009 Apr; 133(4):421-38. PubMed ID: 19289574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
